trending Market Intelligence /marketintelligence/en/news-insights/trending/gu9d60logwldv74dfwjxxa2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

NICE rejects Roche's breast cancer drug on financial grounds

Creating an Efficient Enterprise Wide Credit Risk Management System for a Leading Energy Company

Power and Gas M&A Symposium - 2019 Highlights

Financial Plumbing Prone To Clogging Amid Bank Liquidity Trap

US Commercial Smart Building Projects Set For 56% Annual Revenue Growth Over The Next Five Years


NICE rejects Roche's breast cancer drug on financial grounds

The U.K.'s National Institute for Health and Care Excellence rejected Roche Holding Ltd.'s breast cancer drug Kadcyla on financial grounds.

The government body, which evaluates drugs for use in the National Health Service, said the cost of the £90,000 per year drug did not justify its benefits despite a discount from the company.

NICE's decision is preliminary, however, and the government body is open to consultation.

Around 1,200 people with HER2-positive, unresectable, metastatic breast cancer would be eligible to receive Kadcyla if it were to be recommended.

Patients on Roche's Kadcyla are understood to live up to 9 months longer when compared to those taking the alternative, lapatinib plus capecitabine.